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DNA methylation dynamics in 
mouse preimplantation embryos 
revealed by mass spectrometry
Yoshinori Okamoto1, Naoko Yoshida2, Toru Suzuki3, Nobuhiro Shimozawa4, Maki Asami3, 
Tomonari Matsuda5, Nakao Kojima1, Anthony C. F. Perry3 & Tatsuyuki Takada6
Following fertilization in mammals, paternal genomic 5-methyl-2′-deoxycytidine (5 mC) content 
is thought to decrease via oxidation to 5-hydroxymethyl-2′-deoxycytidine (5 hmC). This reciprocal 
model of demethylation and hydroxymethylation is inferred from indirect, non-quantitative 
methods. We here report direct quantification of genomic 5 mC and 5 hmC in mouse embryos by small 
scale liquid chromatographic tandem mass spectrometry (SMM). Profiles of absolute 5 mC levels 
in embryos produced by in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) were 
almost identical. By 10 h after fertilization, 5 mC levels had declined by ~40%, consistent with active 
genomic DNA demethylation. Levels of 5 mC in androgenotes (containing only a paternal genome) 
and parthenogenotes (containing only a maternal genome) underwent active 5 mC loss in the first 6 h, 
showing that both parental genomes can undergo demethylation independently. We found no evidence 
for net loss of 5 mC 10–48 h after fertilization, implying that any passive ‘demethylation’ following DNA 
replication was balanced by active 5 mC maintenance methylation. However, levels of 5 mC declined 
during development after 48 h, to 1% (measured as a fraction of G-residues) in blastocysts (~96 h). 
5 hmC levels were consistently low (<0.2% of G-residues) throughout development in normal diploid 
embryos. This work directly quantifies the dynamics of global genomic DNA modification in mouse 
preimplantation embryos, suggesting that SMM will be applicable to other biomedical situations with 
limiting sample sizes.
The mammalian genome contains 5-methyl-2′ -deoxycytidine (5 mC) produced by the methylation of 
2′ -deoxycytidine (C), typically in the dinucleotide, CpG1. Genomic 5 mC provides a tier of transcriptional regu-
lation that contributes to cell- and tissue-specific expression; as an approximation, promoters with higher 5 mC 
levels are less active2,3.
In the mouse, de novo DNA methylation is catalyzed by DNA methyl-transferase 3a (Dnmt3a) and Dnmt3b 
and maintained by Dnmt1 (refs 4 and 5). The dynamics of DNA methylation are important because they critically 
influence interactions between DNA and gene regulatory proteins6. Genomic 5 mC is recognized by methyl-DNA 
binding proteins that recruit histone deacetylases7, and Dnmt1, Dnmt3a and Dnmt3b respectively interact with 
H3 lysine 9 methyl transferases, G9a, Suv39h1 and Eset8–10. Trimethyl-H3K9 (H3K9me3) is bound by heterochro-
matin 1 (HP1) which recruits Dnmt1 (refs 9 and 11). Since promoters bound by deacetylated histones, H3K9me2 
and H3K9me3 tend to be inactive, these histone modifications dynamically couple 5 mC to transcriptional 
repression. Contrastingly, unmethylated DNA is associated with acetylated histones, which facilitate transcrip-
tion12. Unmethylated CpG dinucleotides are bound by CXXC finger protein 1 (CFP1) which recruits the H3K4 
methyl-transferase Setd1 (ref. 13); H3K4me2 and H3K4me3 are also associated with transcriptional activation. 
Setd1-mediated H3K4 methylation is linked to the removal of silencing marks H3K9me1, H3K9me2, H3K27me2 
and H4K20me1 via Phf8 (ref. 14).
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Immunofluorescence microscopy using antibodies against 5 mC indicates that soon after fertilization, 5 mC 
decreases markedly in the sperm-derived genome independently of DNA replication or pronucleus forma-
tion15–23. The maternal factor, Stella (also known as Pgc7 or Dppa3) protects the maternal genome from demeth-
ylation, and also protects differentially methylated regions (DMRs) of some imprinted and non-imprinted genes 
in both parental genomes21,24. Recently, bisulfite sequencing has suggested that the maternal genome also under-
goes active zygotic 5 mC depletion18,22. Passive depletion of 5 mC in both parental genomes occurs from the 
first zygotic S-phase until the blastocyst stage via its dilution by semi-conservative DNA replication25,26. Levels 
of 5-hydroxymethyl-2′ -deoxycytidine (5 hmC) in paternal zygotic genomes putatively increase as 5 mC levels 
decrease via Ten-eleven translocation 3- (Tet3-) mediated oxidation19,23, decreasing in subsequent preimplanta-
tion development27.
Comparison between 5 mC and 5 hmC levels will reveal whether their regulation is linked, but immunoflu-
orescence microscopy, which was initially applied to visualize zygotic 5 mC and 5 hmC, is in general suboptimal 
for quantification28. Moreover, the pronounced pre-S-phase reduction in 5 mC suggested by immunofluorescence 
microscopy15 sometimes but not always correlates with bisulfite sequencing analyses of multi-copy genomic ele-
ments including LINEs and early retroposons29–31. In addition, 5 mC and 5 hmC are indistinguishable by standard 
bisulfite sequence analysis32.
No direct quantitative method has been applied to measure 5 mC or 5 hmC content in preimplantation 
embryos and the extent to which zygotic 5 mC is depleted remains unclear. To date, tandem spectrometric (ms/
ms) methods to quantify 5 mC and 5 hmC have not been evaluated for small sample sizes such as those available 
for the study of mouse preimplantation development33,34. This is because conventional ms/ms requires > 20 fmol 
for accurate quantification of 5 mC and 5 hmC; each mature, metaphase II (mII) oocyte contains 200 and 8 amol 
of each respectively.
To address this, we have developed a sensitive, high-throughput small-scale liquid chromatography (lc) ms/ms 
(SMM) method for 5 mC and 5 hmC quantification and apply it to provide an accurate description DNA methyl-
ation in early mouse embryogenesis. Definitive 5 mC and 5 hmC quantification by SMM produces early develop-
mental profiles that are partly compatible with data obtained by conventional methods, but are incompatible with 
the reciprocal model of oxidative 5 mC removal that they suggest for biparental diploid embryos.
Results
Standardization of SMM for 5 mC and 5 hmC. Quantification of DNA methylation in preimplantation 
embryos must be highly sensitive since the sample sizes are so small (typically ≤ 100 cells). We therefore adapted 
ms/ms for ultrasensitive quantification of 5 mC and 5 hmC by modifying sample preparation and chromatogra-
phy for analysis with a high-sensitivity detection system (see Methods). This method, small-scale ms/ms (SMM), 
yielded detection thresholds of 6 fmol (deoxyguanosine, G), 120 amol (5 mC) and 60 amol (5 hmC) (Fig. 1a–c) 
and values for 5 mC and 5 hmC content in different tissues that were similar to previous estimates (Supplementary 
Fig. S1)35,36. To estimate its sensitivity, we applied SMM to 10 ~ 1000 mouse ES cells and obtained stable measure-
ments for 5 mC of 3.54% (of genomic G) from 100 cells, and 0.33% for 5 hmC in 100 cells (Supplementary Fig. 
S2). A value for 5 mC of 3.5% agrees with an estimate for mouse ES cells grown in similar (non-2i) conditions37. 
Validation of SMM for quantification of DNA modifications in ≤ 100 diploid cells paved the way for its applica-
tion to mouse preimplantation development.
Direct measurement of 5 mC during mouse preimplantation development. Quantification 
by SMM of 5 mC in immature, germinal vesicle (GV, prophase I stage) oocytes revealed that levels were simi-
lar to those of mII oocytes (4.69 ± 0.70% vs 4.46 ± 0.46%; p = 0.463) (Fig. 2; Supplementary Table S1; see also 
below). Genomic DNA from caput epididymidal tissue contained a lower 5 mC content than that of mature, 
cauda epididymidal sperm used in subsequent in vitro experiments (caput tissue vs cauda sperm, 4.03 ± 0.08 vs 
4.80 ± 0.22%, p < 0.0001; Supplementary Fig. S1c and Supplementary Table S1).
We applied SMM to embryos produced by natural mating in a time-course, from fertilization to blastocyst 
development at embryonic day 4.5 (E4.5) (3 ≤ n ≤ 5). 5 mC levels decreased to 3.45 ± 0.21% after 6 ~ 8 h (1-cell 
embryos) and more gradually thereafter to 1.09 ± 0.19% by ~96 h (Fig. 2).
Because embryo culture has been reported to affect DNA methylation38, we determined 5 mC profiles during 
preimplantation development following in vitro fertilization (IVF). We also evaluated whether the first polar 
body (Pb1) contributed to 5 mC levels. Irrespective of whether a Pb1 was associated with the oocyte at the time of 
fertilization, 5 mC level profiles in embryos following IVF and natural mating were superimposable (Fig. 2). For 
example, values were similar after ~24 h (p = 0.823) and 48 ~ 50 h (p = 0.070) (Fig. 2). Levels of 5 mC had dropped 
substantially to 2.89 ± 0.20% after 10 h (p < 0.0001 vs mII oocytes; n = 6) (Fig. 2), suggesting that a major phase of 
5 mC removal occurred prior to and during mitotic S-phase, which initiates ~8 h post-fertilization39, with the first 
cell division after 14 ~ 15 h. The global genomic decline in 5 mC levels between 6 and 24 h in IVF was only ~17.5% 
(Fig. 2), a value that is too small to be accounted for entirely by passive demethylation following DNA replication, 
and little or no decline of 5 mC was observed from 10 to 48 h. Although linear regression analyses of subsequent 
development best fit a model in which 5 mC decreased with each cycle of DNA replication (R2 = 0.945; Fig. 2)40, 
the rate of decline accelerated slightly from the 8-cell stage. These patterns seem to reflect a complex balance 
of processes to maintain global 5 mC homeostasis during 1-cell and cleavage stages, including protection from 
demethylation (as, for example, occurs at imprinted loci), active and passive demethylation and maintenance 
methylation (E3.5; Fig. 2)18,21,22. We therefore investigated the relative contributions of these processes to different 
parental genomes in 1- and 2-cell embryos generated by manipulation.
Biparental 5 mC removal prior to the first mitotic S-phase. Accurate determination of 5 mC 
in early embryos requires synchronized cohorts, yet the time of sperm-oocyte union in IVF can only be 
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Figure 1. Standard curves of 2′-deoxyguanosine (G), 5-methyl-2′deoxycytidine (5 mC) and 
5-hydroxymethyl-2′-deoxycytidine (5 hmC). Standard curves for (a) 5 mC, (b) 5 hmC and (c) G and (d) 
representative SMM chromatograms. Specific monitoring of target nucleosides was accomplished based on 
nucleoside-specific fragmentation, which is the loss of deoxyribose-moiety (m/z 116) from each parent ion. 
Peak area was normalized by dividing net peak area of each target by that of its internal standard. X-axes in 
(a–c) represent the quantity (amol) of injected nucleoside and Y-axes plot the ratio of each nucleoside to the 
labelled standard.
Figure 2. Quantification by SMM of 5 mC during mouse preimplantation development. Germinal vesicle 
(GV) oocyte and preimplantation embryo 5 mC content (Y-axis) are plotted against the approximate time 
(h) after fertilization (red arrow). Cell numbers in early (~84 h) and late (~96 h) blastocysts were 32.4 ± 4.23 
(n = 12) and 63.7 ± 13.0 (n = 11) respectively. Values are for embryos produced by natural mating (blue circles) 
and IVF (green triangles). Zero hour values are shown for gametes (Gm) either for mII oocytes (blue circle) 
or an average of sperm plus mII oocyte (green triangle). Approximate times at which different developmental 
stages appear are also indicated. mor, morula; blast, blastocyst. Mean values are ± sd (3 ≤ n ≤ 15). Embryo 
numbers per analysis are given in Supplementary Table S1.
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approximated. One way to achieve synchronization is to inject sperm (intracytoplasmic sperm injection, ICSI) 
at precisely-indicated times (Fig. 3a). Moreover, although ICSI is the method of choice in human assisted repro-
duction41, there are few analyses of whether ICSI affects DNA reprogramming in mammalian early embryos42. 
We therefore applied SMM to the first 24 h of mouse development after ICSI; in our hands, > 70% of ICSI-derived 
1-cell embryos develop to term showing that most have full developmental potential. IVF and ICSI 5 mC profiles 
were similar over the first 24 h (Fig. 3b,c); 5 mC content 3, 6 and 24 h post-ICSI departed by < 3.4% from values at 
corresponding times in IVF. This is consistent with normal genomic DNA methylation kinetics in the first mitotic 
cell cycle of ICSI-derived embryos.
We next manipulated embryos to determine the kinetics of 5 mC in each parental genome. Although immu-
nofluorescence microscopy previously lead to the view that maternal 5 mC levels remain constant in 1-cell mouse 
embryos21,23,27, bisulfite sequence analysis has also suggested that the maternal genome undergoes a net loss of 
5 mC during this period18,22. We investigated this dichotomy by quantifying maternal genomic 5 mC in haploid 
parthenogenotes (ie embryos containing only a maternally-derived genome) (Fig. 3d, 1nP). Parthenogenetic 
5 mC content diminished from 4.46 ± 0.46% to 3.97 ± 0.62% (11.0%, p = 0.073) by 6 h after the initiation of 
development (activation). This decrease was indicative of active, pre-S-phase 5 mC depletion from the maternal 
genome. The 5 mC content in GV oocytes was similar to that of mature mII oocytes (4.69 vs 4.46%, p = 0.463; 
Fig. 3d). The 5 mC content of 2-cell parthenogenotes 24 h post-activation was also similar to that of stage-matched 
2-cell IVF and ICSI embryos, showing that paternal and maternal genomes possessed similar levels of 5 mC by 
24 h (p = 0.385 vs IVF, p = 0.572 vs ICSI) (Fig. 3b–d).
Figure 3. 5 mC profiles determined by SMM in mouse embryos produced by in vitro fertilization and 
different types of micromanipulation. (a) Schematic representation of three of the principal types of 
manipulation used to generate embryos: intracytoplasmic sperm injection (ICSI), parthenogenesis (1nP) and 
androgenesis (1nA). (b) Levels of 5 mC determined by SMM and expressed as a percentage of total G-residues 
in embryos at the times shown (h) after activation of development following in vitro fertilization (IVF). (c) 5 mC 
levels as per (b) except that embryos were generated by ICSI, (d) parthenogenesis (1nP), or (e) androgenesis 
(1nA). (f) Composite of panels (c–e) showing deduced values (ded) for 5 mC levels in androgenotes. Model 1 
(Supplementary Fig. S4) was used to produce the estimated 1nA values but models 1 and 2 gave similar results. 
mII, metaphase II oocyte; Sp, cauda epididymidal sperm. (g) 5 mC levels as per panel (b), except that IVF was 
performed in the presence of the DNA methyl-transferase inhibitor, 5-aza-2′ deoxycytidine (azaC). A bar in 
each histogram marks the approximate time of the first cell division. The zero time-point shows values for mII 
oocytes in (d,f) and the average of mII oocytes plus sperm for (b,c,f,g) and sperm for (e). Mean values are ± sd. 
Embryo numbers per analysis are given in Supplementary Table S1.
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We obtained estimates of paternal 5 mC levels in two ways. First, we measured 5 mC by SMM in androgenotes 
produced by injecting sperm into enucleated mII oocytes (Fig. 3e). Secondly, we estimated paternal 5 mC content 
indirectly by harnessing data from 1-cell embryos and parthenogenotes to produce a subtractive zygotic paternal 
5 mC profile. The profiles generated by the two methods were in good accordance, with slightly higher deduced 
values (Fig. 3f), suggesting that the absence of the maternal genome in androgenotes (1nA) did not greatly impact 
5 mC levels in the paternal genome (Fig. 3f). Taking values that were either deduced or determined directly 
from androgenotes (Fig. 3e), paternal 5 mC content declined a little from that in cauda epididymidal sperm for 
at least 3 h post-fertilization (4.80% vs deduced 4.32%) but then underwent a rapid decline from 4.80 ± 0.22% 
to an experimental value of 2.77 ± 0.63%, a drop of ~42% (p = 0.0005) 3 ~ 6 h post-injection (Fig. 3f). Paternal 
5 mC content changed very little from 6 ~ 24 h, a period straddling the first mitotic division (p = 0.286; Fig. 3e), 
suggesting that 5 mC methylation compensates for passive demethylation during the first S-phase and 1- to 2-cell 
division.
Simultaneous post-meiotic paternal genome methylation and demethylation. To investi-
gate paternal DNA methylation in the first embryonic cell cycle, we performed IVF in the presence of the DNA 
methyl-transferase (Dnmt) inhibitor, 5-aza-2′ deoxycytidine (azaC). 5 mC levels 6 h post-IVF were similar in the 
presence or absence of azaC (p = 0.246; Fig. 3b,g), suggesting that little or no net DNA methylation normally 
occurs from 0 to 6 h. However, by 24 h, 5 mC levels in the azaC group were 80.5% of controls (p = 0.005; Fig. 3b,g). 
This suggests that the decline in 5 mC 6 ~ 24 h post-fertilization is accompanied by balancing de novo or mainte-
nance DNA methylation.
Early embryonic genome 5 hmC profiles. Quantification by SMM can reveal relationships between 
5 mC and 5 hmC content in early development. Levels of 5 hmC were 0.18 ± 0.16% of total G (n = 3) in sperm and 
0.15 ± 0.09% (n = 6) in mII oocytes (Fig. 4a). Following natural mating, steady-state 5 hmC levels progressively 
declined from 0.19 ± 0.09% in 1-cell embryos (n = 3) to 0.05 ± 0.01% in late blastocysts (n = 5) with an unex-
plained increase (p = 0.036, n = 4) from 4- to 8-cell stages (Fig. 4a). The 1-cell 5 hmC content was similar to 6 h 
values in IVF (0.12%, n = 2) and ICSI (0.12 ± 0.05%, n = 5), suggesting that over-all, 5 hmC does not accumulate 
in 1-cell embryos in the first 6 h27,29,43. 5 hmC can be oxidatively converted by Tet enzymes into 5-formylC (5fC) 
and 5-carboxylC (5caC)34, but we were unable to detect 5fC or 5caC ~8 h post-fertilization, with respective quan-
tification thresholds of 480 amol and 360 amol (Supplementary Fig. S3). Our measurements suggest that average 
parental 5 hmC content was 0.16% (but n = 1 in which 5 hmC was detected) 3 h post-ICSI and 0.12 ± 0.05% 
(n = 5) after 6 h (Fig. 5a). These values are approaching detection threshold levels and should be interpreted with 
caution. However, our measurements provided an average that did not distinguish between levels in each parental 
genome. To address this directly, we determined 5 hmC levels in androgenotes. We detected 5 hmC levels of 1.35% 
in androgenotes 6 h post-ICSI, reflecting a ~9-fold increase (n = 3; Fig. 5a). This marked increase in the amount 
of genomic 5 hmC in androgenotes but not in biparental embryos was too great to be accounted for by a depletion 
of similar magnitude in the maternal genome. Immunofluorescence microscopy (Fig. 5b,c) suggested that 5 hmC 
was abundant in androgenotes and the male pronuclei of ICSI embryos, but produced a net over-estimate of 
5 hmC in ICSI embryos compared to SMM that warrants further investigation (Fig. 5c).
Discussion
We here employed SMM to quantify maternal and paternal 5 mC and 5 hmC content prior to and immediately 
after the activation of development, revealing definitive epigenetic dynamics in early mouse embryos. Such com-
parative profiling is problematic with immunofluorescence microscopy, which is affected by chromatin states, 
particularly compaction in sperm and mII oocytes. For example, 5 mC levels in mII oocytes and immediately 
post-fertilization have not been compared23. Moreover, levels of 5 mC and 5 hmC determined by quantitative 
Figure 4. Quantification by SMM of 5 hmC during mouse preimplantation development. (a) Content 
(% total G) of 5 hmC (Y-axis) in metaphase II oocytes (mII) and preimplantation embryos at different 
preimplantation developmental time points. bla1 and bla2 respectively refer to blastocysts ~84 h and ~96 h 
post-fertilization. Mean values are ± sd (3 ≤ n ≤ 5). Embryos were produced by natural mating. 5 mC levels in 
embryos produced by natural mating (b) or IVF (c) are shown for comparison, with mean values shown ± sd 
(3 ≤ n ≤ 7). Embryo numbers are given in Supplementary Table S1.
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immunofluorescence using different antibodies cannot be compared. By contrast, SMM enables the simple, direct 
measurement of absolute 5 mC and 5 hmC levels that may be compared in a given sample.
This addition of more detailed measurements addresses prevailing models of early embryonic epigenetic 
regulation and delineates conditions that they must satisfy. Both bisulfite sequencing and immunofluorescence 
microscopy indicate a drop in zygotic genome methylation prior to the first mitotic S-phase15,17,23. The extent of 
demethylation is at variance depending on the conventional method used, with bisulfite sequencing typically 
suggesting a smaller decrease23,29 (discussed in ref. 44). This might a priori be because bisulfite chemistry in ear-
lier work has not always distinguished between 5 mC, 5 hmC or other modifications45 but SMM suggests that the 
contribution from 5 hmC is extremely small: typically ~0.2%. Although the precise values at these near-threshold 
levels should be interpreted with caution, this illustrates the principle that SMM is applicable to multiple DNA 
modifications in a given sample, unlike either bisulfite sequencing or immunofluorescence microscopy, which 
requires a predetermined and discriminatory antibody.
SMM lacks the intracellular resolution required for parental genome discrimination, but this limitation could 
be addressed by analyzing parthenogenotes or androgenotes, which respectively contain only maternal and 
paternal genomes (Fig. 3d–f). The results confirm active paternal and maternal 5 mC depletion prior to mitotic 
S-phase; active depletion of maternal 5 mC was inferred recently from bisulfite sequence analyses18,22. In one 
reciprocal model23, zygotic 5 mC is removed by oxidation to 5 hmC: paternal genomic 5 mC content declines 
as 5 hmC content increases (ie producing reciprocity) and in Tet3-deficient zygotes, paternal 5 hmC levels are 
low and 5 mC levels high19,23. Profiles of 5 mC and 5 hmC produced by SMM may exhibit this reciprocal rela-
tionship over all in normal biparental 1-cell embryos (Fig. 5), but do not distinguish between parental genomes. 
However, our quantification sets an upper limit on the level of paternal 5 hmC increase of ~0.3% in normal 1-cell 
embryos (Fig. 5). A 5 hmC level increase of this magnitude (0.3%) would be smaller than the observed decrease 
in 5 mC in ICSI (4.60 ± 0.39 vs 3.44 ± 0.23%, 3 vs 6 h; Fig. 3c), suggesting either anomalously rapid dynamics 
of 5 hmC removal43 or that there is no strong mechanistic correlation between 5 mC and 5 hmC from 3 to 6 h 
post-fertilization. SMM is thus consistent with previous immunofluorescence studies suggesting that demethyla-
tion precedes S-phase and occurs independently of hydroxymethylation and pronucleus formation17,46.
A straightforward reciprocal relationship between 5 mC and 5 hmC is also challenged by high-resolution spa-
tiotemporal immunofluorescence microscopy of zygotic 5 hmC and 5 mC27,47. Enforced Tet3 expression in vivo 
causes an increase in 5 hmC with no obvious decrease in 5 mC48. Furthermore, we have shown that maternal 5 mC 
content declines 3 ~ 6 h post-activation of development (Fig. 3d) even though the maternal pronucleus lacks Tet3 
(ref. 19), suggesting that the maternal genome undergoes Tet3-independent 5 mC depletion, possibly involving 
Tet1 (ref. 48). Collectively, our findings suggest that 5 hmC is not necessarily an oxidative intermediate in zygotic 
5 mC removal, and 5 hmC may constitute a discrete gene-regulatory mark associated with 5 hmC-binding pro-
teins with roles in early development49,50. However, we noted a marked increase in 5 hmC levels in androgenotes 
coincidental with the decline in 5 mC levels (Fig. 5a). There is no evidence for or against a causal relationship 
between 5 mC and 5 hmC level changes in androgenotes in these data, but they point to a trans-regulatory role of 
paternal 5 hmC levels by the maternal genome or its associated (eg pronuclear) components. In sum, the recipro-
cal model of 5 mC oxidation to 5 hmC by Tet3 does not explain the levels or distributions of each.
Figure 5. Comparative 5 mC and 5 hmC profiles for ICSI and androgenesis. (a) Levels of 5 mC (dotted lines) 
and 5 hmC (solid lines) determined by SMM and expressed as a percentage of total G-residues in embryos at 
the times shown (h) after activation. A value of 0.00 was taken for samples in which 5 hmC was not detected. 
Embryos were generated by intracytoplasmic sperm injection (ICSI, green) or androgenesis (1nA, orange). 
Data (2 ≤ n ≤ 3) are expressed as means (± sd). Zero hour time points show the average of combined values 
for sperm plus mII oocyte (ICSI) or sperm alone (1nA). (b) Fluorescence images of a haploid androgenote 
(1nA, top row), an embryo generated by ICSI (central row) and a haploid parthenogenote (1nA) 6 h after sperm 
injection (1nP and ICSI) or parthenogenic activation (1nP). Embryos were labeled with anti-5 hmC antibodies 
(green) and propidium iodide (DNA, red). Scale bar, 10 μ m. (c) Pixel quantification (± s.e.m.) of n = 5 samples 
of (b), showing fluorescence levels normalized against PI (DNA). For paternal pronuclei in 1nA and ICSI 
(ICSI m), and maternal pronuclei in 1nP and ICSI (ICSI f), p > 0.05. Embryo numbers per analysis are given in 
Supplementary Table S1.
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We have demonstrated the utility of SMM for 5 mC, 5 hmC, 5fC and 5caC, but expect that the method 
can be extended to any poly-nucleic acid modification or adduct, including N6-methyladenosine in RNA, 
N6-methyladenine and 4 mC in prokaryotic DNA and mutagens that include so-called DMBA-DNA and 
etheno-DNA adducts. The analytical power of SMM in small samples promises to facilitate monitoring of 
anti-cancer chemotherapy based on DNA cross-linking agents such as Cisplatin51,52. The association of global 
DNA hypomethylation with pluripotency37 suggests that SMM could provide a rapid quantitative cellular potency 
indicator in small population samples. Locus-specific SMM should also be possible following chromatin immu-
noprecipitation (ChIP) with antibodies against chromatin binding proteins: SMM-ChIP.
Methods
Chemicals. 2′ -Deoxyguanosine (G) was obtained from Sigma-Aldrich Co. (St. Louis, MO). 15N5-
2′ -Deoxyguanosine (15N5-G) was purchased from Cambridge Isotope Laboratories Inc. (Andover, MA). 
5-Methyl-2′ -deoxycytidine (5 mC) was obtained from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). 
5-(Methyl-d3)-2′ -deoxycytidine (5 mC-d3) was purchased from Toronto Research Chemicals Inc. (Ontario, 
Canada). 5-Hydroxymethyl-2′ -deoxycytidine (5 hmC), 5-formyl-2′ -deoxycytidine (5fC) and 5-carboxyl-2′ -deox-
ycytidine (5caC) were from Berry and Associates Inc. (Dexter, MI). 5-(Hydroxymethyl-d2)-2′ -deoxycitidine 
(5 hmC-d2) was synthesized at Meijo University. All other chemicals used were of the highest grade commercially 
available.
ES cell culture. Mouse embryonic stem (ES) cells ES-D3 obtained from ATCC were cultured on mitomy-
cin C-treated mouse embryonic fibroblast. Medium was consisted with knockout Dullbecco’s modified Eagle 
medium (Gibco) containing 15% knockout serum replacement (KSR, Gibco), 1% antibiotics, 1% non-essential 
amino acids, 2 mM glutamine, 0.1 mM 2-mercaptoethanol, and 1000 U/ml leukemia inhibitory factor (LIF, 
Wako). Culture medium was changed every day and cells were sub-cultured every 3–4 d.
Experimental animals. All animal experiments strictly observed national statutes and local institutional 
guidelines. Mice (B6D2F1 and ICR) were supplied by SLC (Shimizu Laboratory Supplier, Kyoto) or CLEA (Tokyo) 
in Japan or were bred from stocks in-house or otherwise supplied by Charles River (L’Arbresle, France) (UK). 
Tissues from cynomolgus monkeys (Macaca fascicularis) were obtained from the Tsukuba Primate Research 
Center (TPRC), National Institutes of Biomedical Innovation (NIBIO) according to approval from, and guide-
lines of, the NBIO Animal Care Committee. Mouse maintenance and usage was according to the law and in 
observance of host institution guidelines.
Preparation and culture oocytes and embryos. Eight-to-10-week-old B6D2F1 females were supero-
vulated using standard serial injections of pregnant mare serum gonadotropin (PMSG) followed 48 h later by 
human chorionic gonadotropin (hCG). 14 ~ 16 h after hCG injection, oviductal metaphase II (mII) oocytes were 
collected in M2 medium and cumulus cells removed by hyaluronidase (Sigma) treatment as described previ-
ously17,53. Randomly-selected mII oocytes and mII oocytes with no extant first polar body (Pb1) gave similar 
values for 5 mC. For 96 h profiles, embryos were obtained by in vitro fertilization (IVF, see below) or by naturally 
mating superovulated B6D2F1 females and B6D2F1 males. For IVF, freshly-isolated cauda epididymidal sperm 
were incubated in 100 μ l pre-warmed human tubal fluid (HTF, Millipore) for 1 h and following sperm disper-
sal, 1 ~ 3 μ l of the suspension transferred to 200 μ l of HTF containing cumulus oophorous complexes. After 2 h, 
nascent embryos were washed thoroughly and cultured in KSOM (Millipore) supplemented with 1 mg/ml BSA 
(Sigma). For natural mating, 2-cell embryos were collected into M2 medium from plugged females 1.5 days post 
coitum (dpc) and transferred to pre-warmed KSOM (Millipore) containing 1 mg/ml BSA for continued culture. 
In all experiments, oocyte incubation and embryo culture were in humidified CO2 [5% (v/v) in air] at 37 °C. Prior 
to analysis, samples were collected in a minimum volume and stored at − 80 °C in 1.5 ml tubes.
Genomic DNA extraction and treatment. Genomic DNA extraction from tissues and cultured cells 
employed a spin column (high pure PCR template preparation kit, Roche Mannheim, Germany) according to 
the instruction manual. Cauda epididymidal sperm from of 8–12 week old B6D2F1 males were washed once in 
PBS prior to DNA extraction. DNA from gametes, embryos and in experiments using 10 to 1000 ES-D3 cells 
was extracted on ultra-microspin columns (nucleospin tissue XS, Macherey-Nagel GmbH and Co. KG, Duren, 
Germany) and the total recovered DNA (4.08 ± 0.66 ng from 1000 cells) subjected to small-scale lc-ms/ms 
(SMM). Genomic DNA digestion was performed as reported with minor modifications54. Briefly, < 1 μ g DNA 
was digested at 37 °C for 3 h with nuclease P1 (4U, Wako Pure Chemical Industries, Ltd., Osaka, Japan) and 
alkaline phosphatase (3U, Wako) in 100 μ l of buffer mixture (3 mM sodium acetate [pH 5.3] containing 1 mM 
2-mercaptoethanol, 2 mM ZnSO4) followed by the addition of 20 μ l 50 mM Tris-HCl (pH8.5) and continued 
incubation for 3 h. Enzymes were methanol-precipitated, and the supernatant containing nucleoside evaporated 
and stored at − 80 °C. Each digest was reconstituted in 100 μ l of internal standard solution containing 5 mC-d3 
(0.1 nM), 5 hmC-d2 (0.1 nM) and 15N5-G (1 nM) before being subjected to SMM.
DNA analysis by SMM. Analysis of genomic DNA samples by small-scale ms/ms (SMM) was performed on 
high performance liquid chromatography (HPLC) (Prominence series, Shimadzu, Kyoto, Japan) equipped with a 
triple quadrupole mass spectrometer (API4000 system, AB Sciex, Foster City, CA). Sample aliquots (60 μ l) were 
separated at 40 °C using a reverse-phase column (TSKgel ODS-100V, 4.6 mm × 75 mm × 3 μ m; Tosoh, Tokyo, 
Japan) in isocratic mode with a mobile phase (methanol-10 mM ammonium formate [20:80 {v/v}]) at a flow rate 
of 0.3 ml/min. Where target-ionization was insufficient, gradient HPLC elution (mobile phase A, 10 mM ammo-
nium formate; mobile phase B, methanol; gradient mode, 0–12 min, linear gradient to 15% B; 12–15 min, isocratic 
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with 15% B; 15–20 min, linear gradient to 30% B) was sometimes performed to remove impurities and residual 
buffer from the sample.
SMM is adapted for ultrasensitive quantification of 5 mC and 5 hmC in three principal ways. First, the 
triple-quadropole mass spectrometer is specialized for high-sensitivity quantification. Secondly, the buffer 
concentration employed for enzymatic digestion of DNA was reduced 10-fold relative to standard protocols, 
allowing efficient ionization of target molecules. Finally, HPLC was optimized by employing a short column 
(75 mm × 4.6 mm inner diameter) packed with small particles (3 mm diameter). This avoided diffusion of tar-
get compounds and permitted isocratic elution for rapid and simultaneous analysis of 5 mC and 5 hmC. Stable, 
isotope-labeled nucleosides were used as internal standards for 5 mC, 5 hmC and G.
Elution of 5 mC, 5 hmC and G was respectively at 4.1, 5.0 and 5.3 min on isocratic mode (total running time, 
12 min) or respectively at 9.8, 13.3 and 14.4 min on gradient mode (20 min). Mass spectral analysis was carried 
out in positive ion mode with nitrogen as the nebulizing gas. Ionization was performed under the following 
conditions: curtain gas, 10; collision gas, 8; ion source gas 1, 60; ion source gas 2, 60; ion source voltage, 4500 V; 
ion source temperature, 400 °C. Positive ions were acquired in MRM mode. MRM transitions were monitored as 
follows: 5 mC (m/z 242 → 126), 5 mC-d3 (m/z 245 → 129), 5 hmC (m/z 258 → 142), 5 hmC-d2 (m/z 260 → 144), 
G (m/z 268 → 152), 15N5-G (m/z 273 → 157). The proportion (%) of C that was 5 mC or 5 hmC in each sample 
was given by: % 5 mC or 5 hmC  =  [(value for 5 mC or 5 hmC)/(value for G)]x 100. The mouse genome contains 
21% C55.
In some cases, 5 hmC content was measured using a Xevo TQ-S (Waters, Manchester, UK) with an ACQUITY 
UPLC system (Waters). Sample aliquots (10 μ l) were separated at 40 °C on a CORTECS HILIC column 
2.1 mm × 50 mm, 1.7 μ m (Waters) at a flow rate of 0.5 ml/min and subsequently eluted as follows (solvent A, 
10 mM ammonium acetate; solvent B, acetonitrile): 0–1.7 min, isocratic with 95% B; 1.7–4.5 min, linear gradient 
to 20% B. MRM was performed in positive ion mode using nitrogen as the nebulizing gas. Experimental condi-
tions were as follows: ion source temperature, 150 °C; desolvation temperature, 650 °C; desolvation gas flow rate, 
1000 L/h; capillary voltage, 3.0 kV; cone voltage, 10 V; cone gas flow rate, 150 L/h; collision gas, argon; collision 
gas flow rate, 0.12 ml/min.
All SMM analysis was performed within 3 months of genomic DNA sample preparation.
Statistical analysis. Statistical analysis was performed to evaluate significance between two groups using 
Chi-squared or Student’s t-tests. A two-tailed p < 0.05 was regarded as statistically significant.
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